Literature DB >> 1936025

Natural history of severe mitral regurgitation.

J P Delahaye1, J P Gare, E Viguier, F Delahaye, G De Gevigney, H Milon.   

Abstract

The aim of this retrospective study was to review the outcome of 216 patients (pts), investigated for severe mitral regurgitation (MR) between January 1980 and December 1987. Definition of 'severe' was mainly clinical: MR sufficiently advanced for the cardiologist to investigate whether surgery should be imminent. One hundred and sixty two pts (group 1) were operated on; 54 (group 2) did not undergo surgery. Baseline characteristics were similar in the two groups, except for aetiology (less dystrophic and more ischaemic MR in group 2), functional class (88.3% class III or IV in group 1 vs 48.1% in group 2; P = 0.001), pulmonary pressures (lower in group 2) and left ventricular ejection fraction (group 1: 0.66 +/- 0.13; group 2: 0.56 +/- 0.17; P = 0.001). Mean follow-up after hospital admission or surgery was comparable in the two groups (group 1: 3.9 +/- 2.5 years; group 2: 3.5 +/- 2.7 years). Three pts (group 2) were lost to follow-up. Sixty-three pts died; 35 of the 162 operated on; 28 of the 54 non-operated on. Actuarial survival rate at 8 years was 74.0 +/- 4.3% in group 1 vs 33.2 +/- 9.2% in group 2 (P = 0.001). These results confirm that the prognosis of severe MR is poor if it is not operated on, whereas the postoperative course of severe MR, when operated on in time, is good.

Entities:  

Mesh:

Year:  1991        PMID: 1936025     DOI: 10.1093/eurheartj/12.suppl_b.5

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  22 in total

Review 1.  Timing of mitral valve surgery.

Authors:  Maurice Enriquez-Sarano
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

2.  Variation in the Echocardiographic Surveillance of Primary Mitral Regurgitation.

Authors:  Varsha K Tanguturi; Michael K Hidrue; Michael H Picard; Steven J Atlas; Jeffrey B Weilburg; Timothy G Ferris; Katrina Armstrong; Jason H Wasfy
Journal:  Circ Cardiovasc Imaging       Date:  2017-08       Impact factor: 7.792

3.  A method for the morphological analysis of the regurgitant mitral valve using three dimensional echocardiography.

Authors:  A Macnab; N P Jenkins; I Ewington; B J M Bridgewater; T L Hooper; D L Greenhalgh; M R Patrick; S G Ray
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

Review 4.  Quantitative assessment of mitral insufficiency: its advantages and disadvantages.

Authors:  Anna Paszczuk; Susan E Wiegers
Journal:  Heart Fail Rev       Date:  2006-09       Impact factor: 4.214

5.  [Current standard in diagnosis and therapy of heart valve lesions].

Authors:  S Reith; H Körtke; O Volk; H G Klues
Journal:  Z Kardiol       Date:  2001-12

6.  Markers of increased risk in primary mitral regurgitation.

Authors:  Amgad Mentias; Milind Y Desai
Journal:  Ann Transl Med       Date:  2017-08

7.  Impact of left ventricular systolic dysfunction on the outcomes of percutaneous edge-to-edge mitral valve repair using MitraClip.

Authors:  Hidehiro Kaneko; Michael Neuss; Thomas Schau; Jens Weissenborn; Christian Butter
Journal:  Heart Vessels       Date:  2016-03-11       Impact factor: 2.037

8.  Nonischemic mitral regurgitation: prognostic value of nonsustained ventricular tachycardia after mitral valve surgery.

Authors:  Oladipupo Olafiranye; Clare A Hochreiter; Jeffrey S Borer; Phyllis G Supino; Edmund M Herrold; Adam S Budzikowski; Ofek Y Hai; Dany Bouraad; Paul D Kligfield; Leonard N Girardi; Karl H Krieger; O Wayne Isom
Journal:  Cardiology       Date:  2013-02-20       Impact factor: 1.869

9.  Mitral regurgitation determined by radionuclide cardiography: dependence on posture and exercise.

Authors:  H Kelbaek; J Aldershvile; K Skagen; P Hildebrandt; S L Nielsen
Journal:  Br Heart J       Date:  1994-08

10.  Etiology and short-term prognosis of severe mitral regurgitation.

Authors:  Manuel Martínez-Sellés; Miguel Angel García-Fernández; Edith Larios; Mar Moreno; Angel Pinto; José Antonio García-Robles; Esther Pérez-David; Francisco Fernández-Avilés
Journal:  Int J Cardiovasc Imaging       Date:  2008-09-06       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.